Francisca CarvajalRodrigo QueraGonzalo PizarroChristian von MühlenbrockPaulina Núñez2026-03-222026-03-22202610.17235/reed.2026.11861/2026https://doi.org/10.17235/reed.2026.11861/2026https://andeanlibrary.org/handle/123456789/79729In recent decades, the treatment of inflammatory bowel disease (IBD) has changed markedly. Several biological therapies and small molecules have been approved, leading to improved outcomes and quality of life of these patients. However, access to these new therapies is heterogeneous across different countries. In this scenario, the use of thiopurines, through personalized treatment, remain a valid option.enMedicineInflammatory bowel diseaseInflammatory Bowel DiseasesInternal medicineQuality of life (healthcare)AzathioprineDiseaseIntensive care medicineThiopurine methyltransferaseCrohn's diseasearticle